Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Substance Regulation topic
No spam. Unsubscribe anytime.
Wide testimony as committee reconsiders how to regulate high‑potency kratom products
Summary
Senate Bill 557 drew hours of testimony from clinicians, vendors, recovery providers and industry groups about concentrated and synthetic 'cratom' products; sponsors urged restoration of a Senate committee version with product standards while opponents warned bans could harm patients and push users to illicit markets.
The Criminal Justice and Public Safety Committee devoted a major portion of the day to a contentious public hearing on SB557, a bill offered to regulate concentrated and synthetic "cratom" products and to set an under‑21 sales limit.
Senator Deborah Uler, the prime sponsor, urged the panel to restore the Senate committee amendment that would have required potency limits, child‑resistant packaging, labeling of alkaloid content and licensing/enforcement by the Department of Health and Human Services. She said a subsequent floor amendment gutted much of that regulatory framework and left concentrated products largely unaddressed.
Medical witnesses—emergency clinicians and addiction specialists—testified to rising treatment demand, reports of dependence and severe medical outcomes tied to concentrated products. Renee King, an inpatient detox nursing director, told the committee naloxone responses can be inconsistent and toxicology can take days; she said many patients do not know what they bought. Medical witnesses emphasized that concentrated and synthetic isolates differ pharmacologically from whole leaf products.
Industry representatives and natural‑leaf vendors urged the committee to distinguish between traditional whole‑leaf cratom (which some customers use to self‑manage pain) and adulterated synthetics and concentrates sold at convenience stores. Natural‑leaf vendors said many products are lab‑tested and labeled; they warned possession provisions could criminalize consumers who were misled by labeling. Consumer‑advocacy and harm‑reduction groups also cautioned that outright bans could push users to illicit supply chains, citing examples from other states.
A number of witnesses—public‑health groups, hospital clinicians, and the Global Cratom Coalition—asked the committee to target synthetics and adulterated concentrates and to adopt packaging and labeling standards rather than a blanket ban on all products. Others urged an immediate ban on specific synthetic alkaloids, with research exceptions. The committee did not vote on SB557 during the session but heard repeated requests to reconcile the committee amendment, the floor language, and the need to cover concentrated products.
Committee members asked technical questions about definitions ("synthetic," "semisynthetic," "concentrate") and about whether a regulatory approach with potency thresholds and licensing would be administrable. Several legislators said the Senate committee had tried to thread a narrow needle and that the floor amendment left gaps.
The committee left the record open; witnesses provided written testimony, lab data, and recommendations on potency thresholds and labeling. No final committee recommendation was made during the hearing.
